TAILORx established the Oncotype DX® test as a standard of care
In early-stage HR+, HER2-, N0 breast cancer, who may benefit from chemotherapy? Know with confidence which patients may benefit from chemotherapy and which patients may not1-4
Who benefits from chemotherapy
Know with confidence which patients may benefit from chemotherapy and which patients may not1-4
73%
TAILORx patients saved from over-treatment
43%
with low clinical risk* saved from under-treatment
TAILORx shows that clinical risk features alone are not sufficient to determine chemotherapy benefit1,2
73% of patients in TAILORx with high clinical risk* had Recurrence Score results 0-25 and may have been overtreated without the Recurrence Score result**2
43% of patients in TAILORx with Recurrence Score results 26-100 had low clinical risk* and may have been undertreated without the Recurrence Score result**2
*Low clinical risk: tumour size ≤3 cm and Grade 1; tumour size ≤2 cm and Grade 2; tumour size ≤1 cm and Grade 3; High clinical risk: all other cases with known values for grade and tumour size
The largest randomised adjuvant breast cancer treatment trial ever conducted
TAILORx was independently led by
ECOG-ACRIN Cancer Research Group
with sponsorship from the
National Cancer Institute .
Participating cancer research groups included the
Alliance for Clinical Trials in Oncology,
NCIC-Clinical Trials Group, NRG Oncology,
and
SWOG .
Largest ever adjuvant breast cancer treatment clinical trial results - 5-year outcomes, 9-year outcomes and 12-year results5:
Flashcard TAILORx 12-year data
References
- Sparano et al. N Engl J Med. 2015.
- Sparano et al. N Engl J Med. 2018.
- Sparano et al. ASCO 2018.
- Paik et al. J Clin Oncol. 2006.
- Sparano et al. Abstract GS1-05, SABCS 2022.
NIH = National Institute of Health
RS = Recurrence Score result
TAILORx = A Clinical Trial Assigning IndividuaLized Options for Treatment (Rx)
The TAILORx trial was conducted independently by the ECOG-ACRIN Cancer Research Group.
Get in touch
Have questions about Oncotype DX®?
